{"id":9216,"date":"2025-07-22T07:10:15","date_gmt":"2025-07-22T12:10:15","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=9216"},"modified":"2025-07-23T18:30:25","modified_gmt":"2025-07-23T23:30:25","slug":"nanoscope-therapeutics-publishes-mechanism-of-action-details-for-proprietary-broadband-and-fast-multi-characteristic-opsin-technology","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/es\/2025\/07\/22\/nanoscope-therapeutics-publishes-mechanism-of-action-details-for-proprietary-broadband-and-fast-multi-characteristic-opsin-technology\/","title":{"rendered":"Nanoscope Therapeutics publica detalles sobre el mecanismo de acci\u00f3n de su tecnolog\u00eda patentada de opsina multicaracter\u00edstica de banda ancha y alta velocidad."},"content":{"rendered":"<div data-elementor-type=\"wp-post\" data-elementor-id=\"9216\" class=\"elementor elementor-9216\" data-elementor-post-type=\"post\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-6d5ad04f elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"6d5ad04f\" data-element_type=\"section\" data-e-type=\"section\">\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\r\n\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-5bf9bdef\" data-id=\"5bf9bdef\" data-element_type=\"column\" data-e-type=\"column\">\r\n\r\n\t\t\t\t\r\n\t\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\r\n\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-e3a8c93 elementor-widget elementor-widget-text-editor\" data-id=\"e3a8c93\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<h3 style=\"text-align: center;\">Un nuevo estudio destaca la estructura y funci\u00f3n \u00fanicas de la opsina sint\u00e9tica de Nanoscope, lo que respalda su potencial para la restauraci\u00f3n de la visi\u00f3n.<\/h3>\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">DALLAS<\/span><\/span>,\u00a0<span class=\"legendSpanClass\"><span class=\"xn-chron\">22 de julio de 2025<\/span><\/span>\u00a0\u2014\u00a0<a href=\"http:\/\/nanostherapeutics.com\/es\/\" target=\"_blank\" rel=\"nofollow noopener\">Nanoscopio Therapeutics Inc.<\/a>, una empresa de biotecnolog\u00eda comprometida con el desarrollo y la comercializaci\u00f3n de nuevas terapias g\u00e9nicas para pacientes que sufren p\u00e9rdida de visi\u00f3n debido a enfermedades degenerativas de la retina, anunci\u00f3 hoy la publicaci\u00f3n de un art\u00edculo\u00a0<a href=\"https:\/\/www.prnewswire.com\/news-releases\/nanoscope-therapeutics-publishes-mechanism-of-action-details-for-proprietary-broadband-and-fast-multi-characteristic-opsin-technology-302509594.html\" target=\"_blank\" rel=\"nofollow noopener\"><b>\u201c<\/b><b>Topolog\u00eda y mecanismo de la opsina multicaracter\u00edstica (MCO) de banda ancha y r\u00e1pida para la neuromodulaci\u00f3n\u201d,\u201d<\/b><\/a>\u00a0en\u00a0<i>Terapias avanzadas,\u00a0<\/i>una revista revisada por pares en la prestigiosa colecci\u00f3n de Wiley\u00a0<i>Avanzado<\/i>\u00a0Portafolio, conocido por mostrar investigaciones biom\u00e9dicas de alto impacto. El art\u00edculo detalla las caracter\u00edsticas biof\u00edsicas del enfoque terap\u00e9utico patentado de Nanoscope, MCO, incluyendo su estructura y funci\u00f3n \u00fanicas, que utiliza una combinaci\u00f3n de modelado predictivo de prote\u00ednas, ensayos moleculares y electrofisiolog\u00eda.<\/p>\n<p>El art\u00edculo destaca la innovadora investigaci\u00f3n de Nanoscope que respalda el impacto observado en pacientes tratados con la principal terapia de la compa\u00f1\u00eda, MCO-010. Los hallazgos sientan las bases para seguir desarrollando esta tecnolog\u00eda y ayudar a las personas afectadas por diversos grados de p\u00e9rdida de visi\u00f3n debido a enfermedades degenerativas de la retina. Los estudios funcionales mediante registros el\u00e9ctricos demostraron que MCO se activa con la luz ambiental, presenta una cin\u00e9tica de encendido y apagado r\u00e1pida con alta fotosensibilidad y mantiene un amplio rango din\u00e1mico en todo el espectro visible, lo que permite una activaci\u00f3n lum\u00ednica robusta y de primera clase de las c\u00e9lulas que expresan MCO.<\/p>\n<p>\u201cEl mecanismo de acci\u00f3n altamente eficiente de nuestro MCO activable por luz ambiental se debe a su estructura \u00fanica, que permite una sensibilidad a la luz de banda ancha combinada con una cin\u00e9tica de canal r\u00e1pida\u201d, dijo.\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&l=en&o=4471875-1&h=3355908737&u=https%3A%2F%2Fnanostherapeutics.com%2Fwho-we-are%2Fsamarendra-mohanty%2F&a=Dr.+Samarendra+Mohanty%2C+President+%26+Chief+Scientific+Officer\" target=\"_blank\" rel=\"nofollow noopener\">Dr.\u00a0<span class=\"xn-person\">Samarendra Mohanty<\/span>, Presidente y Director Cient\u00edfico<\/a>\u00a0en Nanoscope y autor principal del art\u00edculo. \u201cCon base en esta investigaci\u00f3n y m\u00faltiples estudios cl\u00ednicos, se realiz\u00f3 una presentaci\u00f3n continua.\u00a0<a href=\"https:\/\/www.prnewswire.com\/news-releases\/nanoscope-therapeutics-publishes-mechanism-of-action-details-for-proprietary-broadband-and-fast-multi-characteristic-opsin-technology-302509594.html\" target=\"_blank\" rel=\"nofollow noopener\">Recientemente se inici\u00f3 una solicitud de licencia para productos biol\u00f3gicos ante la FDA para MCO-010.<\/a>, con el potencial de convertirse en la primera terapia independiente del gen para tratar la retinosis pigmentaria.\u201d<\/p>\n<p>Las propiedades topol\u00f3gicas y de activaci\u00f3n funcional \u00fanicas de la prote\u00edna MCO fusionada representan hallazgos novedosos que vinculan la eficacia in vitro e in vivo de esta opsina, fundamental para la neuromodulaci\u00f3n destinada a restaurar la visi\u00f3n en pacientes con enfermedades degenerativas de la retina.<\/p>\n<p><a href=\"https:\/\/psych.uw.edu\/people\/2400\/ione-fine\" target=\"_blank\" rel=\"nofollow noopener\">Dr.\u00a0<span class=\"xn-person\">Ione Fine<\/span>, Profesor, Departamento de Psicolog\u00eda en la\u00a0<span class=\"xn-org\">Universidad de Washington<\/span><\/a>,\u00a0<span class=\"xn-location\">seattle<\/span>, Seg\u00fan coment\u00f3, \u201cEl art\u00edculo ofrece una comparaci\u00f3n exhaustiva del rendimiento de MCO con otras opsinas en desarrollo para el tratamiento de enfermedades degenerativas de la retina. Por ello, proporciona informaci\u00f3n crucial para respaldar la modelizaci\u00f3n computacional y predecir la recuperaci\u00f3n de la visi\u00f3n en pacientes tratados con MCO y otras opsinas\u201d.\u201d<\/p>\n<p><a href=\"https:\/\/advanced.onlinelibrary.wiley.com\/doi\/10.1002\/adtp.202500009\" target=\"_blank\" rel=\"nofollow noopener\">Haga clic aqu\u00ed para acceder al art\u00edculo publicado.<\/a><\/p>\n<p><b>Acerca de Nanoscope Therapeutics Inc.<br class=\"dnr\" \/><\/b>Nanoscope Therapeutics est\u00e1 desarrollando una terapia optogen\u00e9tica independiente del gen para restaurar la visi\u00f3n en millones de pacientes ciegos por enfermedades degenerativas de la retina. Tras los resultados positivos del ensayo cl\u00ednico multic\u00e9ntrico, aleatorizado, doble ciego y controlado con placebo RESTORE Fase 2b para la retinosis pigmentaria (RP), este estudio ha comenzado a desarrollar una terapia optogen\u00e9tica que restaura la visi\u00f3n y que no depende del gen. <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT04945772\">(NCT04945772)<\/a>, la compa\u00f1\u00eda anunci\u00f3 su plan para iniciar un\u00a0<a href=\"https:\/\/nanostherapeutics.com\/es\/2024\/10\/10\/nanoscope-announces-plans-to-submit-bla-for-mco-010-to-treat-retinitis-pigmentosa\/\" target=\"_blank\" rel=\"nofollow noopener\">Presentaci\u00f3n de BLA para MCO-010 para tratar RP<\/a>. De ser aprobado, MCO-010 podr\u00eda convertirse en el tratamiento est\u00e1ndar para pacientes con retinosis pigmentaria (RP), administr\u00e1ndose como una inyecci\u00f3n intrav\u00edtrea \u00fanica en el consultorio sin necesidad de pruebas gen\u00e9ticas. La compa\u00f1\u00eda tambi\u00e9n ha mostrado resultados prometedores en el ensayo cl\u00ednico de fase 2 STARLIGHT de la terapia con MCO-010 en la enfermedad de Stargardt (ES). <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05417126\">(NCT05417126)<\/a> y planes para iniciar un\u00a0<a href=\"https:\/\/nanostherapeutics.com\/es\/2024\/09\/12\/nanoscope-therapeutics-announces-end-of-phase-2-meeting-with-u-s-fda-and-plan-to-initiate-a-phase-3-clinical-trial-of-mco-010-to-treat-stargardt-macular-degeneration\/\" target=\"_blank\" rel=\"nofollow noopener\">Ensayo de registro de fase 3<\/a>\u00a0En 2025, MCO-010 recibi\u00f3 la designaci\u00f3n de v\u00eda r\u00e1pida de la FDA y la designaci\u00f3n de medicamento hu\u00e9rfano para RP y SD. Los programas precl\u00ednicos incluyen la amaurosis cong\u00e9nita de Leber (LCA), en estudios precl\u00ednicos, as\u00ed como un f\u00e1rmaco listo para la solicitud de IND para la atrofia geogr\u00e1fica (GA).<\/p>\n<p><b>Contacto de inversores:<\/b><br class=\"dnr\" \/>Terap\u00e9utica del nanoscopio<br class=\"dnr\" \/>(817) 857-1186<br class=\"dnr\" \/><a href=\"mailto:PR@nanostherapeutics.com\" target=\"_blank\" rel=\"nofollow noopener\">PR@nanostherapeutics.com<\/a><\/p>\n<p>FUENTE Terap\u00e9utica del Nanoscopio<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t<\/section>\r\n\t\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>New research paper highlights the unique structure and function of Nanoscope\u2019s synthetic opsin, supporting its potential in vision restoration DALLAS,\u00a0July 22, 2025\u00a0\u2014\u00a0Nanoscope Therapeutics Inc., a biotechnology company committed to developing and commercializing novel gene therapies for patients suffering vision loss from retinal degenerative diseases, today announced the publication of a paper\u00a0\u201cTopology and Mechanism of Broadband [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":9217,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-9216","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanoscope Therapeutics Publishes Mechanism of Action Details for Proprietary Broadband and Fast Multi-Characteristic Opsin Technology - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/es\/2025\/07\/22\/nanoscope-therapeutics-publishes-mechanism-of-action-details-for-proprietary-broadband-and-fast-multi-characteristic-opsin-technology\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics Publishes Mechanism of Action Details for Proprietary Broadband and Fast Multi-Characteristic Opsin Technology - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/es\/2025\/07\/22\/nanoscope-therapeutics-publishes-mechanism-of-action-details-for-proprietary-broadband-and-fast-multi-characteristic-opsin-technology\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-22T12:10:15+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-23T23:30:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"242\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/07\\\/22\\\/nanoscope-therapeutics-publishes-mechanism-of-action-details-for-proprietary-broadband-and-fast-multi-characteristic-opsin-technology\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/07\\\/22\\\/nanoscope-therapeutics-publishes-mechanism-of-action-details-for-proprietary-broadband-and-fast-multi-characteristic-opsin-technology\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Nanoscope Therapeutics Publishes Mechanism of Action Details for Proprietary Broadband and Fast Multi-Characteristic Opsin Technology\",\"datePublished\":\"2025-07-22T12:10:15+00:00\",\"dateModified\":\"2025-07-23T23:30:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/07\\\/22\\\/nanoscope-therapeutics-publishes-mechanism-of-action-details-for-proprietary-broadband-and-fast-multi-characteristic-opsin-technology\\\/\"},\"wordCount\":559,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/07\\\/22\\\/nanoscope-therapeutics-publishes-mechanism-of-action-details-for-proprietary-broadband-and-fast-multi-characteristic-opsin-technology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_MCO-PublicationFIN.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/07\\\/22\\\/nanoscope-therapeutics-publishes-mechanism-of-action-details-for-proprietary-broadband-and-fast-multi-characteristic-opsin-technology\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/07\\\/22\\\/nanoscope-therapeutics-publishes-mechanism-of-action-details-for-proprietary-broadband-and-fast-multi-characteristic-opsin-technology\\\/\",\"name\":\"Nanoscope Therapeutics Publishes Mechanism of Action Details for Proprietary Broadband and Fast Multi-Characteristic Opsin Technology - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/07\\\/22\\\/nanoscope-therapeutics-publishes-mechanism-of-action-details-for-proprietary-broadband-and-fast-multi-characteristic-opsin-technology\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/07\\\/22\\\/nanoscope-therapeutics-publishes-mechanism-of-action-details-for-proprietary-broadband-and-fast-multi-characteristic-opsin-technology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_MCO-PublicationFIN.jpg\",\"datePublished\":\"2025-07-22T12:10:15+00:00\",\"dateModified\":\"2025-07-23T23:30:25+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/07\\\/22\\\/nanoscope-therapeutics-publishes-mechanism-of-action-details-for-proprietary-broadband-and-fast-multi-characteristic-opsin-technology\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/07\\\/22\\\/nanoscope-therapeutics-publishes-mechanism-of-action-details-for-proprietary-broadband-and-fast-multi-characteristic-opsin-technology\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/07\\\/22\\\/nanoscope-therapeutics-publishes-mechanism-of-action-details-for-proprietary-broadband-and-fast-multi-characteristic-opsin-technology\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_MCO-PublicationFIN.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_MCO-PublicationFIN.jpg\",\"width\":1200,\"height\":627},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/07\\\/22\\\/nanoscope-therapeutics-publishes-mechanism-of-action-details-for-proprietary-broadband-and-fast-multi-characteristic-opsin-technology\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics Publishes Mechanism of Action Details for Proprietary Broadband and Fast Multi-Characteristic Opsin Technology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanoscope Therapeutics publica detalles sobre el mecanismo de acci\u00f3n de su tecnolog\u00eda patentada de opsina multicaracter\u00edstica de banda ancha y alta velocidad - Nanoscope Therapeutics","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/es\/2025\/07\/22\/nanoscope-therapeutics-publishes-mechanism-of-action-details-for-proprietary-broadband-and-fast-multi-characteristic-opsin-technology\/","og_locale":"es_MX","og_type":"article","og_title":"Nanoscope Therapeutics Publishes Mechanism of Action Details for Proprietary Broadband and Fast Multi-Characteristic Opsin Technology - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/es\/2025\/07\/22\/nanoscope-therapeutics-publishes-mechanism-of-action-details-for-proprietary-broadband-and-fast-multi-characteristic-opsin-technology\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2025-07-22T12:10:15+00:00","article_modified_time":"2025-07-23T23:30:25+00:00","og_image":[{"width":1200,"height":242,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"Escrito por":"Nanoscope Therapeutics","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2025\/07\/22\/nanoscope-therapeutics-publishes-mechanism-of-action-details-for-proprietary-broadband-and-fast-multi-characteristic-opsin-technology\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2025\/07\/22\/nanoscope-therapeutics-publishes-mechanism-of-action-details-for-proprietary-broadband-and-fast-multi-characteristic-opsin-technology\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Nanoscope Therapeutics Publishes Mechanism of Action Details for Proprietary Broadband and Fast Multi-Characteristic Opsin Technology","datePublished":"2025-07-22T12:10:15+00:00","dateModified":"2025-07-23T23:30:25+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2025\/07\/22\/nanoscope-therapeutics-publishes-mechanism-of-action-details-for-proprietary-broadband-and-fast-multi-characteristic-opsin-technology\/"},"wordCount":559,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2025\/07\/22\/nanoscope-therapeutics-publishes-mechanism-of-action-details-for-proprietary-broadband-and-fast-multi-characteristic-opsin-technology\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_MCO-PublicationFIN.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2025\/07\/22\/nanoscope-therapeutics-publishes-mechanism-of-action-details-for-proprietary-broadband-and-fast-multi-characteristic-opsin-technology\/","url":"https:\/\/nanostherapeutics.com\/2025\/07\/22\/nanoscope-therapeutics-publishes-mechanism-of-action-details-for-proprietary-broadband-and-fast-multi-characteristic-opsin-technology\/","name":"Nanoscope Therapeutics publica detalles sobre el mecanismo de acci\u00f3n de su tecnolog\u00eda patentada de opsina multicaracter\u00edstica de banda ancha y alta velocidad - Nanoscope Therapeutics","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2025\/07\/22\/nanoscope-therapeutics-publishes-mechanism-of-action-details-for-proprietary-broadband-and-fast-multi-characteristic-opsin-technology\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2025\/07\/22\/nanoscope-therapeutics-publishes-mechanism-of-action-details-for-proprietary-broadband-and-fast-multi-characteristic-opsin-technology\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_MCO-PublicationFIN.jpg","datePublished":"2025-07-22T12:10:15+00:00","dateModified":"2025-07-23T23:30:25+00:00","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2025\/07\/22\/nanoscope-therapeutics-publishes-mechanism-of-action-details-for-proprietary-broadband-and-fast-multi-characteristic-opsin-technology\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2025\/07\/22\/nanoscope-therapeutics-publishes-mechanism-of-action-details-for-proprietary-broadband-and-fast-multi-characteristic-opsin-technology\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/2025\/07\/22\/nanoscope-therapeutics-publishes-mechanism-of-action-details-for-proprietary-broadband-and-fast-multi-characteristic-opsin-technology\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_MCO-PublicationFIN.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_MCO-PublicationFIN.jpg","width":1200,"height":627},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2025\/07\/22\/nanoscope-therapeutics-publishes-mechanism-of-action-details-for-proprietary-broadband-and-fast-multi-characteristic-opsin-technology\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics Publishes Mechanism of Action Details for Proprietary Broadband and Fast Multi-Characteristic Opsin Technology"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"Terap\u00e9utica del nanoscopio","description":"Recuperando la luz de la esperanza","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"Nanoscope Therapeutics, Inc","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"Terap\u00e9utica del nanoscopio"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/9216","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=9216"}],"version-history":[{"count":7,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/9216\/revisions"}],"predecessor-version":[{"id":9225,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/9216\/revisions\/9225"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media\/9217"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=9216"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/categories?post=9216"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/tags?post=9216"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}